TrialCardiovascular diabetology2017

Impact of empagliflozin on subclinical left ventricular dysfunctions and on the mechanisms involved in myocardial disease progression in type 2 diabetes: rationale and design of the EMPA-HEART trial.

Andrea Natali et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.